Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | The efficacy of FLT3 and IDH1/2 inhibitors in patients with AML previously treated with venetoclax

Jan Bewersdorf • 6 Oct 2023
General Updates
Acute Myeloid Leukemia Leukemia Azacitidine Enasidenib Gilteritinib Ivosidenib Midostaurin Quizartinib Venetoclax

Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses advances made in the treatment of acute myeloid leukemia (AML), highlighting the value of FLT3 and IDH1/2 inhibitors. Dr Bewersdorf then shares insights into a retrospective analysis which investigated the efficacy of these targeted agents in patients with AML previously treated with venetoclax, and highlights the need for more research in this space. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Jan Bewersdorf

Ruxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I results
3:26
Ruxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I results
Jan Bewersdorf • 16 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Jan Bewersdorf • 16 Dec 2025
Systematic review and meta-analysis of menin inhibitors for the treatment of AML
3:50
Systematic review and meta-analysis of menin inhibitors for the treatment of AML
Jan Bewersdorf • 16 Dec 2025
A cost-effective analysis of alloSCT versus consolidation chemotherapy in intermediate-risk AML
3:28
A cost-effective analysis of alloSCT versus consolidation chemotherapy in intermediate-risk AML
Jan Bewersdorf • 7 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals